Clinical Trials on Myeloid Malignancies

Total 8814 results

Sichuan University

Recruiting

Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies

Myeloid Malignancies

China
Gilead Sciences

Completed

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Myeloid Malignancies

United States, Australia, United Kingdom
Southwest Hospital, China

Unknown

A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies

Myeloid Malignancies

China
Southwest Hospital, China

Unknown

A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies

Myeloid Malignancies

China
Cristina Gasparetto
Agilent Technologies, Inc.

Active, not recruiting

Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT (NK-DCI)

Lymphoid Malignancies | Myeloid Malignancies

United States
ExCellThera inc.
Memorial Sloan Kettering Cancer Center

Recruiting

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

Cord Blood Transplant | High Risk Myeloid Malignancies

United States
Catherine Bollard
Johns Hopkins University; Children's National Research Institute

Recruiting

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE)

Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia

Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies

United States
iCell Gene Therapeutics
iCar Bio Therapeutics

Not yet recruiting

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

High Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid Leukemia

China
Gruppo Italiano Trapianto di Midollo Osseo

Completed

Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies (GITMO-PHYLOS)

Myeloid Malignancies

Italy
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine

Completed

Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies (UCAML)

Myeloid Hematological Malignancies

United States
Amgen

Completed

Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa

Anemia | Non-Myeloid Malignancies
Amgen

Completed

Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy

Cancer | Non-Myeloid Malignancies
Charite University, Berlin, Germany
University of Leipzig

Unknown

Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells

Acute Myeloid Leukemias | Advanced Hematological Malignancies | Indication for Allogeneic Stem Cell Transplantation | no HLA-identical Donor Available

Germany
Amgen

Completed

Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

Anemia | Non-Myeloid Malignancies
Amgen

Completed

Chemotherapy Related Anemia

Anemia | Non-Myeloid Malignancies
Amgen

Completed

A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

Anemia | Non-Myeloid Malignancies
Amgen

Completed

Darbepoetin Alfa With or Without Intravenous (IV) Iron

Anemia | Non-Myeloid Malignancies
Institut de Recherches Internationales Servier

Recruiting

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Myelodysplastic Syndromes | Relapsed or Refractory Acute Myeloid Leukemia (AML) | Untreated AML | Other IDH1-mutated Positive Hematologic Malignancies

United States, France
St. Jude Children's Research Hospital
Ohio State University; Arog Pharmaceuticals, Inc.

Completed

Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

Acute Myeloid Leukemia

United States
Amgen

Completed

Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia

Leukemia | Myeloid Leukemia | Cancer | Hematologic Malignancies

United States
Amgen

Completed

Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies

Cancer | Anemia | Non-Myeloid Malignancies
Erasca, Inc.

Withdrawn

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies (HERKULES-4)

Acute Myeloid Leukemia

United States
Gilead Sciences

Terminated

Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults (Japanese AML)

Acute Myeloid Leukemia | Hematologic Malignancy

Japan
AvenCell Europe GmbH
Allucent

Recruiting

Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

Germany
Hospices Civils de Lyon

Unknown

Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy (EPREX/LAM-ALLO)

Acute Myeloid Leukemia | Anemia

France
Nanjing Chia-tai Tianqing Pharmaceutical

Recruiting

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

Relapsed/Refractory Acute Myeloid Leukemia (AML)

China
Pharmacosmos A/S

Completed

A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Non-myeloid Malignancies | Chemotherapy Induced Anaemia

India
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia

Childhood Acute Megakaryocytic Leukemia (M7) | Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies

United States
Pfizer

Completed

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

Acute Myeloid Leukemia

Japan
Zenith Epigenetics

Withdrawn

Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML

Acute Myeloid Leukemia | Lymphoproliferative Malignancies

United States
Adam Olszewski

Active, not recruiting

Removing Transfusion Dependence as a Barrier to Hospice Enrollment (BRUOG-407)

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Leukemia | Hematologic Malignancy | Myeloma

United States
Memorial Sloan Kettering Cancer Center

Completed

Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation

Lymphoma | Acute Myeloid Leukemia | Leukemia | Myelodysplastic Syndrome | Myeloma | Hematological Malignancy

United States
St. Jude Children's Research Hospital

Completed

The Oronasal Microbiota in Pediatric Oncology Patients

Acute Myeloid Leukemia | Bone Marrow Transplantation | Hematologic Malignancy

United States
Amgen

Completed

Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy

Cancer | Anemia | Non-Myeloid Malignancies
National Cancer Institute (NCI)

Completed

Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia

Untreated Adult Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Childhood Acute Promyelocytic Leukemia (M3) | Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

United States
Agios Pharmaceuticals, Inc.

Completed

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Myelodysplastic Syndrome | Hematologic Malignancies | Acute Myeloid Leukemia (AML)

United States, France
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies

Lymphoma | Acute Myeloid Leukemia | Multiple Myeloma
M.D. Anderson Cancer Center

Recruiting

Off-the-shelf NK Cells + SCT for Myeloid Malignancies

Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Myeloid Malignancies

United States
M.D. Anderson Cancer Center

Recruiting

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Hematopoietic and Lymphoid System Neoplasm | Myeloproliferative Neoplasm

United States
St. Jude Children's Research Hospital
Cookies for Kids' Cancer

Terminated

Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
Kura Oncology, Inc.

Recruiting

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Neoplasms by Histologic Type | Acute Myeloid Leukemia | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | AML | Acute Leukemia | Hematologic Malignancy | NPM1 Mutation | AML With Mutated NPM1 | KMT2Ar | MLL Rearrangement

United States
AbbVie
Genentech, Inc.

Completed

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL)

Japan
Ciceri Fabio

Completed

Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant (FLAT-Auto)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Transplant-Related Hematologic Malignancy

Italy
Gilead Sciences
California Institute for Regenerative Medicine (CIRM)

Completed

CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United Kingdom
Amgen

Terminated

Darbepoetin Alfa and Anemia of Cancer

Neoplasms | Carcinoma | Cancer | Anemia | Non-Myeloid Malignancies | Anemia of Cancer
Amgen

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | AML | Myelodysplastic Syndrome | MDS | Non-Hodgkins Lymphoma | NHL

United States, Australia, Italy, France, Greece, Japan
Centre Hospitalier Universitaire de Nīmes

Recruiting

Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies. (TIPHI)

Leukemia | Chronic Leukemia | Myelogenous Leukemia | BCR-ABL Positive Acute Myeloid Leukemia

France
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia

Childhood Acute Lymphoblastic Leukemia | Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia

Childhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies

United States

Clinical Trials on Myeloid Malignancies

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations